These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 26390218

  • 1. KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome.
    Furio L, Pampalakis G, Michael IP, Nagy A, Sotiropoulou G, Hovnanian A.
    PLoS Genet; 2015 Sep; 11(9):e1005389. PubMed ID: 26390218
    [Abstract] [Full Text] [Related]

  • 2. KLK5 and KLK7 Ablation Fully Rescues Lethality of Netherton Syndrome-Like Phenotype.
    Kasparek P, Ileninova Z, Zbodakova O, Kanchev I, Benada O, Chalupsky K, Brattsand M, Beck IM, Sedlacek R.
    PLoS Genet; 2017 Jan; 13(1):e1006566. PubMed ID: 28095415
    [Abstract] [Full Text] [Related]

  • 3. Cathelicidin represents a new target for manipulation of skin inflammation in Netherton syndrome.
    Zingkou E, Pampalakis G, Sotiropoulou G.
    Biochim Biophys Acta Mol Basis Dis; 2020 Oct 01; 1866(10):165831. PubMed ID: 32442469
    [Abstract] [Full Text] [Related]

  • 4. Netherton syndrome: skin inflammation and allergy by loss of protease inhibition.
    Hovnanian A.
    Cell Tissue Res; 2013 Feb 01; 351(2):289-300. PubMed ID: 23344365
    [Abstract] [Full Text] [Related]

  • 5. A proinflammatory role of KLK6 protease in Netherton syndrome.
    Zingkou E, Pampalakis G, Charla E, Nauroy P, Kiritsi D, Sotiropoulou G.
    J Dermatol Sci; 2019 Jul 01; 95(1):28-35. PubMed ID: 31255470
    [Abstract] [Full Text] [Related]

  • 6. Transgenic Kallikrein 14 Mice Display Major Hair Shaft Defects Associated with Desmoglein 3 and 4 Degradation, Abnormal Epidermal Differentiation, and IL-36 Signature.
    Gouin O, Barbieux C, Leturcq F, Bonnet des Claustres M, Petrova E, Hovnanian A.
    J Invest Dermatol; 2020 Jun 01; 140(6):1184-1194. PubMed ID: 32169475
    [Abstract] [Full Text] [Related]

  • 7. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.
    Wang S, Olt S, Schoefmann N, Stuetz A, Winiski A, Wolff-Winiski B.
    Exp Dermatol; 2014 Jul 01; 23(7):524-6. PubMed ID: 24848304
    [Abstract] [Full Text] [Related]

  • 8. Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome.
    Furio L, de Veer S, Jaillet M, Briot A, Robin A, Deraison C, Hovnanian A.
    J Exp Med; 2014 Mar 10; 211(3):499-513. PubMed ID: 24534191
    [Abstract] [Full Text] [Related]

  • 9. Cocktails of KLK5 Protease Inhibitors and Anti-TNFα Therapeutics: an Effective Treatment for Netherton Syndrome.
    Zingkou E, Pampalakis G, Sotiropoulou G.
    J Clin Immunol; 2022 Apr 10; 42(3):597-605. PubMed ID: 35040012
    [Abstract] [Full Text] [Related]

  • 10. Dual antibody inhibition of KLK5 and KLK7 for Netherton syndrome and atopic dermatitis.
    Chavarria-Smith J, Chiu CPC, Jackman JK, Yin J, Zhang J, Hackney JA, Lin WY, Tyagi T, Sun Y, Tao J, Dunlap D, Morton WD, Ghodge SV, Maun HR, Li H, Hernandez-Barry H, Loyet KM, Chen E, Liu J, Tam C, Yaspan BL, Cai H, Balazs M, Arron JR, Li J, Wittwer AJ, Pappu R, Austin CD, Lee WP, Lazarus RA, Sudhamsu J, Koerber JT, Yi T.
    Sci Transl Med; 2022 Dec 14; 14(675):eabp9159. PubMed ID: 36516271
    [Abstract] [Full Text] [Related]

  • 11. Physiological and pathological roles of kallikrein-related peptidases in the epidermis.
    Kishibe M.
    J Dermatol Sci; 2019 Aug 14; 95(2):50-55. PubMed ID: 31279501
    [Abstract] [Full Text] [Related]

  • 12. Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model.
    Briot A, Lacroix M, Robin A, Steinhoff M, Deraison C, Hovnanian A.
    J Invest Dermatol; 2010 Dec 14; 130(12):2736-42. PubMed ID: 20703245
    [Abstract] [Full Text] [Related]

  • 13. The 420K LEKTI variant alters LEKTI proteolytic activation and results in protease deregulation: implications for atopic dermatitis.
    Fortugno P, Furio L, Teson M, Berretti M, El Hachem M, Zambruno G, Hovnanian A, D'Alessio M.
    Hum Mol Genet; 2012 Oct 01; 21(19):4187-200. PubMed ID: 22730493
    [Abstract] [Full Text] [Related]

  • 14. LEKTI is localized in lamellar granules, separated from KLK5 and KLK7, and is secreted in the extracellular spaces of the superficial stratum granulosum.
    Ishida-Yamamoto A, Deraison C, Bonnart C, Bitoun E, Robinson R, O'Brien TJ, Wakamatsu K, Ohtsubo S, Takahashi H, Hashimoto Y, Dopping-Hepenstal PJ, McGrath JA, Iizuka H, Richard G, Hovnanian A.
    J Invest Dermatol; 2005 Feb 01; 124(2):360-6. PubMed ID: 15675955
    [Abstract] [Full Text] [Related]

  • 15. Netherton syndrome: defective kallikrein inhibition in the skin leads to skin inflammation and allergy.
    Furio L, Hovnanian A.
    Biol Chem; 2014 Sep 01; 395(9):945-58. PubMed ID: 25153381
    [Abstract] [Full Text] [Related]

  • 16. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome.
    Briot A, Deraison C, Lacroix M, Bonnart C, Robin A, Besson C, Dubus P, Hovnanian A.
    J Exp Med; 2009 May 11; 206(5):1135-47. PubMed ID: 19414552
    [Abstract] [Full Text] [Related]

  • 17. Genetic activation of Nrf2 reduces cutaneous symptoms in a murine model of Netherton syndrome.
    Muzumdar S, Koch M, Hiebert H, Bapst A, Gravina A, Bloch W, Beer HD, Werner S, Schäfer M.
    Dis Model Mech; 2020 Jun 01; 13(5):. PubMed ID: 32457102
    [Abstract] [Full Text] [Related]

  • 18. A Potent and Selective Kallikrein-5 Inhibitor Delivers High Pharmacological Activity in Skin from Patients with Netherton Syndrome.
    Liddle J, Beneton V, Benson M, Bingham R, Bouillot A, Boullay AB, Brook E, Cryan J, Denis A, Edgar E, Ferrie A, Fouchet MH, Grillot D, Holmes DS, Howes A, Krysa G, Laroze A, Lennon M, McClure F, Moquette A, Nicodeme E, Santiago B, Santos L, Smith KJ, Thorpe JH, Thripp G, Trottet L, Walker AL, Ward SA, Wang Y, Wilson S, Pearce AC, Hovnanian A.
    J Invest Dermatol; 2021 Sep 01; 141(9):2272-2279. PubMed ID: 33744298
    [Abstract] [Full Text] [Related]

  • 19. Kallikrein 5 inhibitors identified through structure based drug design in search for a treatment for Netherton Syndrome.
    White GV, Edgar EV, Holmes DS, Lewell XQ, Liddle J, Polyakova O, Smith KJ, Thorpe JH, Walker AL, Wang Y, Young RJ, Hovnanian A.
    Bioorg Med Chem Lett; 2019 Mar 15; 29(6):821-825. PubMed ID: 30691925
    [Abstract] [Full Text] [Related]

  • 20. LEKTI domains D6, D7 and D8+9 serve as substrates for transglutaminase 1: implications for targeted therapy of Netherton syndrome.
    Wiegmann H, Valentin F, Tarinski T, Liebau E, Loser K, Traupe H, Oji V.
    Br J Dermatol; 2019 Nov 15; 181(5):999-1008. PubMed ID: 30801672
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.